Epilepsy and the inflammasome: targeting inflammation as a novel therapeutic strategy for seizure disorders

Edye, M. E., Walker, L. E., Sills, G. J., Allan, S. M. and Brough, D. (2014) Epilepsy and the inflammasome: targeting inflammation as a novel therapeutic strategy for seizure disorders. Inflammasome, 1(1), pp. 36-43. (doi:10.2478/infl-2014-0004)

[img]
Preview
Text
177485.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

322kB

Abstract

Epilepsy is the most common serious brain disorder worldwide. Recent evidence from experimental models of epilepsy and clinical brain tissue from epilepsy surgery suggests inflammation may play a pathological role in this disorder. Activation of a multimolecular protein complex termed the ‘inflammasome’ occurs during inflammation to drive the innate immune response. Inflammasome activation, with release of inflammatory mediators including interleukin-1β and high-mobility group box-1, may play a crucial role in the development of epilepsy (epileptogenesis) after brain insult. Immunomodulatory drugs targeting the inflammasome pathway may represent a novel antiepileptogenic treatment strategy for epilepsy. This review summarises the current literature surrounding inflammasome activation and epilepsy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Sills, Dr Graeme
Authors: Edye, M. E., Walker, L. E., Sills, G. J., Allan, S. M., and Brough, D.
College/School:College of Medical Veterinary and Life Sciences
Journal Name:Inflammasome
Publisher:De Gruyter
ISSN:2300-102X
Copyright Holders:Copyright © 2014 ME Edye et al.
First Published:First published in Inflammasome 1(1):36-43
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record